bearish
Hansoh Pharma IPO Preview: A Decent Story Tarnished by a Huge Pre-IPO Dividend
487 Views12 Feb 2019 07:34
Hansoh Pharmaceutical (HANSOH HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. According to press reports, Hansoh...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 9-minute read)
Discussions
(Paid Plans Only)
- Rakuten (4755 JP): Lyft IPO’s Big Lift Unlikely to Lead to a Sustained Re-Rating04 Mar 2019
- Lyft IPO Preview: Maybe We'll Just Walk?04 Mar 2019
- Last Week in GER Research: API/Sigma, M1, Eclipx/Mcmillan and Hansoh IPO18 Feb 2019
- Hansoh Pharma IPO Preview: A Decent Story Tarnished by a Huge Pre-IPO Dividend12 Feb 2019
- CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates29 Jan 2019
- WuXi AppTec IPO Valuation: Bull/Bear Case DCF Scenarios11 Dec 2018
- Junshi Biosciences IPO Valuation: Sensibly Priced with Upside at the Low-End10 Dec 2018
x